MARKET

ACUT

ACUT

ACCUSTEM SCIENCES INC
OTCMQB
0.239
+0.080
+50.38%
Closed 15:54 08/17 EDT
OPEN
0.239
PREV CLOSE
0.159
HIGH
0.239
LOW
0.239
VOLUME
5.00K
TURNOVER
1.20K
52 WEEK HIGH
2.250
52 WEEK LOW
0.152
MARKET CAP
3.84M
P/E (TTM)
-2.3259
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ACUT last week (0810-0814)?
Weekly Report · 1d ago
Based on the provided financial report articles, I generated the title for the article: **"ACUT Financial Report: Q2 2026 Earnings and Balance Sheet Update"** Please note that the title is generated based on the provided data and may not be the actual title of the article.
Press release · 3d ago
Weekly Report: what happened at ACUT last week (0803-0807)?
Weekly Report · 08/10 09:23
Weekly Report: what happened at ACUT last week (0727-0731)?
Weekly Report · 08/03 09:23
Weekly Report: what happened at ACUT last week (0720-0724)?
Weekly Report · 07/27 09:24
Weekly Report: what happened at ACUT last week (0713-0717)?
Weekly Report · 07/20 09:23
Weekly Report: what happened at ACUT last week (0706-0710)?
Weekly Report · 07/13 09:24
Weekly Report: what happened at ACUT last week (0629-0703)?
Weekly Report · 07/06 09:25
More
About ACUT
AccuStem Sciences, Inc. is a clinical-stage diagnostics company. It is focused on developing and commercializing a suite of genomic tests that support decision-making along the entire continuum of oncology care. It focuses on its proprietary genomic tests, MicroRNA Signature Classifier (MSC) for patients with lung nodules and StemPrintER for patients with early-stage breast cancer. The MSC test, a 24-micro-RNA (miRNA) assay designed to help determine whether lung nodules identified by low-dose computer tomography (LDCT) screening, are benign or malignant. StemPrintER, a 20-gene prognostic assay intended to predict the risk of distant recurrence (DR) in luminal (ER+/HER2-negative) breast cancer patients. The assay is developed to measure the stemness of tumors, or how much a tumor behaves like stem cells, which could indicate how likely a cancer is to recur or be resistant to standard treatments, ultimately impacting how patients are managed by their multidisciplinary care team.

Webull offers AccuStem Sciences Inc stock information, including OTCMQB: ACUT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACUT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ACUT stock methods without spending real money on the virtual paper trading platform.